How the PCAOB Inspection Regime Affects China Concept Stock Delisting Risks

The passage of the Holding Foreign Companies Accountable Act (HFCAA) in December 2020 triggered a structural repricing of China concept stocks listed in New York, compressing valuations by an average of 62% from peak to trough between February 2021 and October 2022 for the 261 Chinese issuers then trading on the NYSE and Nasdaq. That discount reflected a binary tail risk: the mandatory delisting of any foreign issuer whose auditor had not been inspected by the Public Company Accounting Oversight Board (PCAOB) for three consecutive years. By December 2022, the PCAOB had secured complete access to audit work papers in mainland China and Hong Kong, removing the immediate trigger. The 2024–2025 cycle, however, has introduced a new layer of uncertainty. The PCAOB’s second full inspection cycle in China has produced a materially higher deficiency rate — 42% of audit engagements reviewed in 2024 contained at least one Part I deficiency, versus 28% in the 2022–2023 cycle, according to the PCAOB’s 2024 Staff Update published in January 2025. This deterioration, combined with the U.S. Securities and Exchange Commission’s (SEC) December 2024 interpretive guidance on “foreign government control” under the Accelerating Holding Foreign Companies Accountable Act (AHFCAA), has re-opened the delisting risk channel for a subset of issuers. For CFOs and sponsors of China concept stocks evaluating a Hong Kong dual-primary listing under HKEX Chapter 19C, the regulatory architecture now requires a jurisdictional analysis that goes beyond audit access alone.

The PCAOB Inspection Regime: From Binary Risk to Graded Exposure

The Statutory Framework and the 2022 Reset

The HFCAA, signed into law on 18 December 2020, amended the Sarbanes-Oxley Act of 2002 to require the SEC to identify any issuer that had retained a public accounting firm not subject to PCAOB inspection for three consecutive years. Upon identification, the issuer’s securities would be prohibited from trading on U.S. national exchanges. The legislation covered approximately 261 Chinese issuers with a combined market capitalisation of approximately USD 1.9 trillion as of 31 December 2020, per SEC staff estimates. The PCAOB’s inability to inspect audit firms in mainland China and Hong Kong had persisted since the board’s inception in 2003, owing to jurisdictional objections raised by the China Securities Regulatory Commission (CSRC) and the Ministry of Finance under Article 177 of China’s Securities Law, which prohibited the transfer of audit work papers offshore without regulatory approval.

On 16 December 2022, the PCAOB issued a formal determination that it had secured complete access to inspect and investigate audit firms in mainland China and Hong Kong, following a 10-week on-site inspection programme conducted from September to November 2022. The determination removed the immediate delisting threat for all Chinese issuers. The PCAOB’s 2022 inspection reports, published on 10 May 2023, covered 50 audit engagements across the two major Chinese audit networks — the Big Four’s Chinese affiliates and the domestic firms — and found a deficiency rate of 28%.

The 2024–2025 Cycle: Deficiency Rate Expansion

The PCAOB’s 2024 inspection cycle, completed in December 2024 and published on 15 January 2025, covered 72 audit engagements across eight Chinese audit firms. The deficiency rate rose to 42%, with 30 engagements containing at least one Part I deficiency — defined as a failure to obtain sufficient appropriate audit evidence to support the audit opinion. The increase was concentrated in three areas: revenue recognition testing (deficiency rate of 67% among engagements reviewed), impairment assessments of long-lived assets (54%), and related-party transaction identification and disclosure (48%). The PCAOB specifically flagged that certain Chinese auditors had not independently tested management’s assumptions in goodwill impairment models, relying instead on management-prepared documentation without independent corroboration.

The 2024 cycle also included the first full inspections of two mid-tier Chinese audit firms — ShineWing Certified Public Accountants and Zhongxin Certified Public Accountants — which had not been subject to PCAOB inspection during the 2022 cycle. Both firms recorded deficiency rates above 50%. The PCAOB’s 2025 inspection plan, announced on 12 February 2025, targets 85 audit engagements across 10 firms, including the first inspection of a Chinese audit firm with a concentration of VIE-structured issuers.

The Regulatory Repercussion: SEC Interpretive Guidance on “Foreign Government Control”

On 17 December 2024, the SEC’s Division of Corporation Finance issued Staff Legal Bulletin No. 14M (SLB 14M), providing interpretive guidance on the “foreign government control” prong of the AHFCAA. The AHFCAA, signed into law on 29 December 2023, reduced the delisting timeline from three consecutive years of non-inspection to two consecutive years and added a new disqualification criterion: any issuer that the SEC determines is “owned or controlled by a foreign government” that has prevented PCAOB access. SLB 14M clarified that the determination would be based on a “totality of the circumstances” test, including: (i) whether a foreign government holds more than 50% of the issuer’s voting power; (ii) whether the issuer’s board or senior management includes individuals appointed or approved by a foreign government; and (iii) whether the issuer operates under a regulatory framework that grants a foreign government the power to direct its operations or financial reporting.

The guidance has direct implications for China concept stocks with state-owned enterprise (SOE) shareholders or entities operating under the CSRC’s revised overseas listing filing regime, effective from 23 March 2023. Under the CSRC’s Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (Order No. 195), any issuer that files for overseas listing must submit a “special note” on the impact of PRC laws and regulations on its operations and financial reporting. The SEC’s staff has indicated that this filing requirement itself does not constitute control, but the substance of the CSRC’s review authority — including the power to suspend or terminate an overseas listing application under Article 12 of Order No. 195 — could be considered a control factor under SLB 14M.

The VIE Structure and Audit Access: A Jurisdictional Tangle

The VIE Audit Work Paper Problem

Variable interest entity (VIE) structures, which account for approximately 85% of China concept stocks listed in New York as of 31 December 2024, per data compiled by Dealogic and HKEX filings, present a unique audit access challenge. Under a standard VIE arrangement, the Hong Kong-listed or Cayman-incorporated holding company — the issuer — has no direct equity ownership of the operating entities in mainland China. The operating entities are owned by PRC nationals or domestic companies, and the issuer’s control is exercised through a series of contractual agreements — including exclusive call options, equity pledge agreements, and power of attorney arrangements — rather than through equity ownership.

The PCAOB’s inspection authority extends to the audit work papers of the consolidated entity, including the VIE’s operating subsidiaries. However, the PRC’s State Administration of Foreign Exchange (SAFE) and the CSRC have maintained that audit work papers relating to the operating entities — as distinct from those of the holding company — remain subject to Article 177 of the Securities Law, which prohibits the transfer of “documents, materials, and information” relating to securities issuance and trading offshore without CSRC approval. The PCAOB’s 2022 determination of complete access was predicated on the CSRC’s agreement to facilitate access through a “coordinated review mechanism” established in August 2022. The mechanism requires the PCAOB to submit inspection requests to the CSRC, which then coordinates with the relevant audit firm to produce work papers. The PCAOB has confirmed that it received full access in the 2022 and 2024 cycles, but the mechanism’s reliance on CSRC intermediation introduces a procedural dependency that the SEC’s SLB 14M guidance treats as a potential control factor.

The Hong Kong Dual-Listing Workaround

HKEX Chapter 19C, introduced in November 2018 and amended in January 2023, provides a secondary listing pathway for “Grandfathered” and “Non-Grandfathered” issuers that have a primary listing on a “Qualifying Exchange” — defined as the NYSE, Nasdaq, or the London Stock Exchange’s Main Market. As of 31 December 2024, 24 China concept stocks had completed a secondary listing in Hong Kong, with an aggregate market capitalisation of approximately HKD 3.2 trillion, per HKEX monthly data. A further 12 issuers have filed for dual-primary listing under HKEX Chapter 19C, which converts the Hong Kong listing from secondary to primary status, thereby eliminating the dependency on the U.S. listing for continued trading.

The dual-primary listing structure under Chapter 19C requires the issuer to comply with HKEX’s full set of continuing obligations under Chapter 13 of the Main Board Listing Rules, including the requirement to file annual and interim financial statements in compliance with Hong Kong Financial Reporting Standards (HKFRS) or International Financial Reporting Standards (IFRS). The HKEX does not require PCAOB inspection as a condition of listing; the Hong Kong listing is audited by a Hong Kong-registered auditor that is subject to inspection by the Hong Kong Accounting and Financial Reporting Council (AFRC), established under the Accounting and Financial Reporting Council Ordinance (Cap. 588). The AFRC has been a full member of the International Forum of Independent Audit Regulators (IFIAR) since 2022 and conducts its own inspection programme of Hong Kong audit firms.

The practical effect of a dual-primary listing in Hong Kong is to sever the delisting link between the U.S. listing and the issuer’s continued trading status. If the SEC delists the U.S. shares under the AHFCAA, the Hong Kong-listed shares continue trading on the Main Board. However, the U.S. delisting triggers a mandatory conversion of the U.S.-traded American Depositary Receipts (ADRs) into Hong Kong-listed shares, governed by the deposit agreement between the issuer, the depositary bank (typically JPMorgan Chase, Citibank, or Deutsche Bank), and the ADR holders. The conversion mechanics are set out in the issuer’s Form F-6 registration statement filed with the SEC. The conversion rate and associated costs — typically 0.5% to 1.0% of the ADR value, per the deposit agreement — are borne by the ADR holder.

The Cost-Benefit Calculus of a 2025–2026 Dual Listing

Direct and Indirect Costs

The direct costs of a dual-primary listing in Hong Kong under Chapter 19C are well-documented. The HKEX listing fee is HKD 150,000 for the initial application fee plus an annual listing fee of HKD 145,000 for Main Board issuers with a market capitalisation above HKD 10 billion. The sponsor fees — payable to the sole or joint sponsors, which must be licensed under the Securities and Futures Ordinance (SFO) for Type 6 (advising on corporate finance) regulated activity — range from HKD 15 million to HKD 40 million for a standard Chapter 19C application, per fee surveys conducted by the Hong Kong Investment Funds Association (HKIFA) in Q3 2024. Legal fees for Hong Kong counsel and U.S. counsel, including the preparation of the listing document and the verification of the VIE structure, range from HKD 8 million to HKD 20 million. The total direct cost for a mid-cap issuer (market capitalisation of HKD 5 billion to HKD 20 billion) is approximately HKD 35 million to HKD 70 million.

The indirect costs are more significant. The dual-primary listing requires the issuer to maintain dual financial reporting — U.S. GAAP or IFRS for the U.S. filing and HKFRS or IFRS for the Hong Kong filing. The incremental audit cost for the Hong Kong filing is approximately HKD 5 million to HKD 10 million per annum, per estimates from the Big Four audit firms’ Hong Kong practices. The issuer must also maintain a Hong Kong-based company secretary and a registered office in Hong Kong, with associated annual costs of HKD 1 million to HKD 2 million.

The Valuation Discount and the Liquidity Premium

The valuation discount for China concept stocks that have completed a dual-primary listing in Hong Kong has narrowed materially since 2022. As of 31 December 2024, the average price differential between the Hong Kong-listed shares and the U.S.-traded ADRs for the 24 dual-listed issuers was 3.2%, down from 12.8% in December 2022, per Bloomberg cross-market pricing data. The narrowing reflects increased liquidity in Hong Kong — the average daily turnover for dual-listed China concept stocks on HKEX was HKD 4.2 billion in Q4 2024, compared with HKD 1.8 billion in Q4 2022 — driven by the inclusion of these stocks in the Southbound Stock Connect programme under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.

The Southbound Stock Connect, which allows mainland Chinese investors to trade Hong Kong-listed shares through their domestic brokerage accounts, has been a material liquidity driver. As of 31 December 2024, 18 of the 24 dual-listed China concept stocks were eligible for Southbound trading, with mainland investors holding an aggregate 8.7% of the free float, per HKEX monthly data. The inclusion criteria require the issuer to have a market capitalisation above HKD 20 billion and a daily turnover above HKD 200 million for the preceding 12 months. The liquidity premium from Southbound access has been estimated at 15% to 25% of the valuation discount, per a December 2024 research note by Goldman Sachs.

The 2025–2026 Regulatory Horizon: Three Scenarios

Scenario One: Renewed PCAOB Access Restrictions

The most adverse scenario for China concept stocks is a renewal of PCAOB access restrictions, triggered by a geopolitical event or a change in CSRC policy. The PCAOB’s 2024 determination of complete access is subject to annual review; the board can issue a new determination of non-access at any time if it concludes that the CSRC or the Ministry of Finance has impeded inspection or investigation. The PCAOB’s 2025 Inspection Plan, published on 12 February 2025, includes a contingency provision for “expedited re-determination” if access is denied during the 2025 cycle. If the PCAOB issues a non-access determination for the 2025 cycle, the two-year clock under the AHFCAA would start from the first year of non-access, meaning that issuers audited by Chinese firms would face delisting in 2027.

Scenario Two: SEC Enforcement of the “Control” Prong

The SEC’s SLB 14M guidance is not self-executing; it requires the SEC to issue individual determinations for each issuer. The SEC’s Division of Corporation Finance has indicated that it will begin issuing Section 104(i)(3) determinations under the AHFCAA in Q2 2025, starting with issuers that have a PRC state-owned enterprise as a controlling shareholder. As of 31 December 2024, 37 China concept stocks listed in New York had a PRC government entity or SOE as the beneficial owner of more than 30% of the voting power, per SEC EDGAR filings. The SEC’s determination would trigger a delisting process that requires the issuer to file a Form 25 with the SEC to delist its securities, with trading ceasing 10 days thereafter.

Scenario Three: The Hong Kong Listing as a Structural Hedge

The most likely scenario for 2025–2026 is that the PCAOB retains access, the SEC issues a limited number of control-based determinations, and the majority of China concept stocks pursue a dual-primary listing in Hong Kong as a structural hedge. The HKEX’s 2024 consultation paper on proposed amendments to Chapter 19C, published on 20 November 2024, proposes to reduce the minimum market capitalisation requirement for a dual-primary listing from HKD 40 billion to HKD 20 billion and to waive the “Qualifying Exchange” requirement for issuers that have been listed on a recognised stock exchange for at least five years. The consultation period closed on 20 February 2025, and the HKEX has indicated that the amendments will take effect in Q3 2025. If adopted, the amendments would expand the pool of eligible issuers from 24 to approximately 45, per HKEX staff estimates.

Actionable Takeaways

1. CFOs of China concept stocks with a U.S. listing should commission a jurisdictional audit under SLB 14M’s “totality of the circumstances” test by Q2 2025, specifically analysing whether a PRC government entity holds more than 30% of voting power or whether the CSRC’s Order No. 195 filing regime constitutes a control factor under the SEC’s interpretive guidance.

2. Issuers with a VIE structure should verify that their audit firm has completed the PCAOB’s 2024 inspection cycle without a Part I deficiency in the revenue recognition or related-party transaction areas, as a deficiency in these areas increases the probability of a PCAOB re-inspection and potential non-access determination.

3. The HKEX’s proposed amendments to Chapter 19C, expected to take effect in Q3 2025, reduce the minimum market capitalisation threshold to HKD 20 billion — issuers currently below this threshold should prepare the listing document and sponsor engagement by Q2 2025 to be ready for the filing window.

4. The cost-benefit analysis of a dual-primary listing should incorporate the Southbound Stock Connect liquidity premium of 15% to 25%, which offsets approximately one-third of the direct and indirect costs of the listing over a three-year horizon.

5. Issuers that receive a Section 104(i)(3) determination from the SEC should initiate the ADR-to-Hong Kong share conversion process within 10 business days, as the Form 25 delisting process provides a 10-day trading window before the U.S. shares cease trading.